About Cessation Therapeutics
Cessation Therapeutics is a company based in San Jose (United States) founded in 2017.. Cessation Therapeutics has raised $6.76 million across 4 funding rounds from investors including HHS and National Institute on Drug Abuse. Cessation Therapeutics offers products and services including Anti-fentanyl Monoclonal Antibody. Cessation Therapeutics operates in a competitive market with competitors including MorphoSys, Genmab, Indivior, Forty Seven and Compass Therapeutics, among others.
- Headquarter San Jose, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cessation Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$6.76 M (USD)
in 4 rounds
-
Latest Funding Round
$1 M (USD), Series A
Mar 29, 2024
-
Investors
HHS
& 1 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cessation Therapeutics
Cessation Therapeutics offers a comprehensive portfolio of products and services, including Anti-fentanyl Monoclonal Antibody. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Antibody that captures fentanyl to prevent brain entry and overdose effects.
Unlock access to complete
Unlock access to complete
Funding Insights of Cessation Therapeutics
Cessation Therapeutics has successfully raised a total of $6.76M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $1 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series A — $1.0M
-
First Round
First Round
(01 Jun 2019)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2024 | Amount | Series A - Cessation Therapeutics | Valuation |
investors |
|
| Oct, 2023 | Amount | Grant - Cessation Therapeutics | Valuation |
investors |
|
| May, 2022 | Amount | Series A - Cessation Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cessation Therapeutics
Cessation Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and National Institute on Drug Abuse. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Scientific research on drug use and addiction is supported.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cessation Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cessation Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cessation Therapeutics Comparisons
Competitors of Cessation Therapeutics
Cessation Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MorphoSys, Genmab, Indivior, Forty Seven and Compass Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Antibody therapeutics for cancer and autoimmune diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for opioid addiction treatment are developed and commercialized.
|
|
| domain | founded_year | HQ Location |
Therapies for diverse diseases including oncology are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer treatment are discovered and developed.
|
|
| domain | founded_year | HQ Location |
Therapies for pain and addiction treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cessation Therapeutics
Frequently Asked Questions about Cessation Therapeutics
When was Cessation Therapeutics founded?
Cessation Therapeutics was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Where is Cessation Therapeutics located?
Cessation Therapeutics is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
Who is the current CEO of Cessation Therapeutics?
John D Harkey is the current CEO of Cessation Therapeutics.
Is Cessation Therapeutics a funded company?
Cessation Therapeutics is a funded company, having raised a total of $6.76M across 4 funding rounds to date. The company's 1st funding round was a Series A of $5.76M, raised on Jun 01, 2019.
What does Cessation Therapeutics do?
Cessation Therapeutics was founded in 2017 and is headquartered in San Jose, United States. Focus is placed on biotechnology for developing immunotherapy vaccines targeting addiction disorders, including those related to opioids, heroin, morphine, fentanyl, alcohol, and nicotine. Drug conjugate molecules are created by linking haptens to immunogenic proteins, which are then formulated with immune stimulants to generate antibodies against substances of abuse and support immunity induction.
Who are the top competitors of Cessation Therapeutics?
Cessation Therapeutics's top competitors include Forty Seven, Indivior and Genmab.
What products or services does Cessation Therapeutics offer?
Cessation Therapeutics offers Anti-fentanyl Monoclonal Antibody.
Who are Cessation Therapeutics's investors?
Cessation Therapeutics has 2 investors. Key investors include HHS, and National Institute on Drug Abuse.